Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	123322
DOI	10.4292/wjgpt.123322
Country	United States

Category	Medicine, General & Internal
Manuscript Type	Meta-Analysis
Article Title	Comparative efficacy and safety of biologic therapies in moderate-to-severe Crohn’s disease: A systematic review and Bayesian network meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Hakim Ullah Wazir, Kartik Mehta, Nayanika Tummala, Muhammad Rafiqul Islam, Nimra Ehsan, Saniya Ishtiaq, Maryam Muzaffar, Muhammad Maaz, Ammarah Tariq, Muhammad Kamran Hassan, Muhammad Shabbir, Anish Kumar and Salim Surani
Funding Agency and Grant Number
Corresponding Author	Salim Surani, FACP, FCCP, MD, Professor, Department of Medicine, University of Houston, 4302 University Drive, Houston, TX 77004, United States. srsurani@hotmail.com
Key Words	Crohn’s disease; Inflammatory bowel disease; Biologics; Adalimumab; Risankizumab; Mirikizumab; Immunomodulators
Core Tip	This systematic review and Bayesian network meta-analysis found that adalimumab, risankizumab, and mirikizumab were the most effective biologics for inducing clinical remission in moderate-to-severe Crohn’s disease. Risankizumab was the only treatment to show a significant benefit in endoscopic healing, while no biologic showed a clear advantage over placebo for overall clinical response. Safety was broadly similar across treatments. Overall, adalimumab regimens and risankizumab/mirikizumab appeared most favorable for remission.
Citation	Wazir HU, Mehta K, Tummala N, Islam MR, Ehsan N, Ishtiaq S, Muzaffar M, Maaz M, Tariq A, Hassan MK, Shabbir M, Kumar A, Surani S. Comparative efficacy and safety of biologic therapies in moderate-to-severe Crohn’s disease: A systematic review and Bayesian network meta-analysis. World J Gastrointest Pharmacol Ther 2026; In press DOI: https://doi.org/10.4292/wjgpt.123322
PDF	123322-in-press.pdf

Received	2026-05-15 07:26
Peer-Review Started	2026-05-15 07:27
First Decision by Editorial Office Director	2026-05-26 10:30
Return for Revision	2026-05-26 10:30
Revised	2026-06-27 07:50
Publication Fee Transferred
Second Decision by Editor	2026-09-10 02:43
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-09-10 09:19
Articles in Press	2026-09-10 09:19
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com